Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Arterioscler Thromb Vasc Biol ; 35(1): 102-10, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25395613

ABSTRACT

OBJECTIVE: Diabetic hypertriglyceridemia is thought to be primarily driven by increased hepatic de novo lipogenesis. However, experiments in animal models indicated that insulin deficiency should decrease hepatic de novo lipogenesis and reduce plasma triglyceride levels. APPROACH AND RESULTS: To address the discrepancy between human data and genetically altered mouse models, we investigated whether insulin-deficient diabetic mice had triglyceride changes that resemble those in diabetic humans. Streptozotocin-induced insulin deficiency increased plasma triglyceride levels in mice. Contrary to the mouse models with impaired hepatic insulin receptor signaling, insulin deficiency did not reduce hepatic triglyceride secretion and de novo lipogenesis-related gene expression. Diabetic mice had a marked decrease in postprandial triglycerides clearance, which was associated with decreased lipoprotein lipase and peroxisome proliferator-activated receptor α mRNA levels in peripheral tissues and decreased lipoprotein lipase activity in skeletal muscle, heart, and brown adipose tissue. Diabetic heterozygous lipoprotein lipase knockout mice had markedly elevated fasting plasma triglyceride levels and prolonged postprandial triglycerides clearance. CONCLUSIONS: Insulin deficiency causes hypertriglyceridemia by decreasing peripheral lipolysis and not by an increase in hepatic triglycerides production and secretion.


Subject(s)
Diabetes Mellitus, Experimental/metabolism , Hypertriglyceridemia/metabolism , Insulin/blood , Lipolysis , Liver/metabolism , Streptozocin , Triglycerides/blood , Adipose Tissue, Brown/metabolism , Animals , Biomarkers/blood , Blood Glucose/metabolism , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/genetics , Hypertriglyceridemia/blood , Hypertriglyceridemia/chemically induced , Hypertriglyceridemia/genetics , Lipogenesis , Lipoprotein Lipase/deficiency , Lipoprotein Lipase/genetics , Lipoprotein Lipase/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Muscle, Skeletal/metabolism , Myocardium/metabolism , PPAR alpha/genetics , PPAR alpha/metabolism , PPAR delta/genetics , PPAR delta/metabolism , Postprandial Period , RNA, Messenger/metabolism , Signal Transduction , Time Factors
2.
J Lipid Res ; 55(4): 645-58, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24493834

ABSTRACT

The rodent heart accumulates TGs and lipid droplets during fasting. The sources of heart lipids could be either FFAs liberated from adipose tissue or FAs from lipoprotein-associated TGs via the action of lipoprotein lipase (LpL). Because circulating levels of FFAs increase during fasting, it has been assumed that albumin transported FFAs are the source of lipids within heart lipid droplets. We studied mice with three genetic mutations: peroxisomal proliferator-activated receptor α deficiency, cluster of differentiation 36 (CD36) deficiency, and heart-specific LpL deletion. All three genetically altered groups of mice had defective accumulation of lipid droplet TGs. Moreover, hearts from mice treated with poloxamer 407, an inhibitor of lipoprotein TG lipolysis, also failed to accumulate TGs, despite increased uptake of FFAs. TG storage did not impair maximal cardiac function as measured by stress echocardiography. Thus, LpL hydrolysis of circulating lipoproteins is required for the accumulation of lipids in the heart of fasting mice.


Subject(s)
Lipid Droplets/physiology , Lipoprotein Lipase/physiology , Myocardium/metabolism , Animals , Fasting , Hydrolysis , Lipid Metabolism , Lipoproteins/blood , Male , Membrane Proteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , PPAR alpha/genetics , Perilipin-2 , Perilipin-5 , Proteins/metabolism , Systole , Triglycerides/blood
3.
Endocrinology ; 153(11): 5143-9, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22948212

ABSTRACT

Although studies in vitro and in hypothyroid animals show that thyroid hormone can, under some circumstances, modulate the actions of low-density lipoprotein (LDL) receptors, the mechanisms responsible for thyroid hormone's lipid-lowering effects are not completely understood. We tested whether LDL receptor (LDLR) expression was required for cholesterol reduction by treating control and LDLR-knockout mice with two forms of thyroid hormone T(3) and 3,5-diiodo-l-thyronine. High doses of both 3,5-diiodo-l-thyronine and T(3) dramatically reduced circulating total and very low-density lipoprotein/LDL cholesterol (∼70%) and were associated with reduced plasma T(4) level. The cholesterol reduction was especially evident in the LDLR-knockout mice. Circulating levels of both apolipoprotein B (apo)B48 and apoB100 were decreased. Surprisingly, this reduction was not associated with increased protein or mRNA expression of the hepatic lipoprotein receptors LDLR-related protein 1 or scavenger receptor-B1. Liver production of apoB was markedly reduced, whereas triglyceride production was increased. Thus, thyroid hormones reduce apoB lipoproteins via a non-LDLR pathway that leads to decreased liver apoB production. This suggests that drugs that operate in a similar manner could be a new therapy for patients with genetic defects in the LDLR.


Subject(s)
Cholesterol/blood , Diiodothyronines/pharmacology , Liver/metabolism , Receptors, LDL/metabolism , Triiodothyronine/pharmacology , Animals , Apolipoproteins B/blood , Liver/drug effects , Mice , Mice, Knockout , Receptors, LDL/genetics , Scavenger Receptors, Class B/metabolism , Thyroxine/blood
4.
J Lipid Res ; 52(4): 732-44, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21205704

ABSTRACT

Diacylglycerol (DAG) acyl transferase 1 (Dgat1) knockout ((-/-)) mice are resistant to high-fat-induced obesity and insulin resistance, but the reasons are unclear. Dgat1(-/-) mice had reduced mRNA levels of all three Ppar genes and genes involved in fatty acid oxidation in the myocardium of Dgat1(-/-) mice. Although DGAT1 converts DAG to triglyceride (TG), tissue levels of DAG were not increased in Dgat1(-/-) mice. Hearts of chow-diet Dgat1(-/-) mice were larger than those of wild-type (WT) mice, but cardiac function was normal. Skeletal muscles from Dgat1(-/-) mice were also larger. Muscle hypertrophy factors phospho-AKT and phospho-mTOR were increased in Dgat1(-/-) cardiac and skeletal muscle. In contrast to muscle, liver from Dgat1(-/-) mice had no reduction in mRNA levels of genes mediating fatty acid oxidation. Glucose uptake was increased in cardiac and skeletal muscle in Dgat1(-/-) mice. Treatment with an inhibitor specific for DGAT1 led to similarly striking reductions in mRNA levels of genes mediating fatty acid oxidation in cardiac and skeletal muscle. These changes were reproduced in cultured myocytes with the DGAT1 inhibitor, which also blocked the increase in mRNA levels of Ppar genes and their targets induced by palmitic acid. Thus, loss of DGAT1 activity in muscles decreases mRNA levels of genes involved in lipid uptake and oxidation.


Subject(s)
Diacylglycerol O-Acyltransferase/metabolism , Muscle, Skeletal/metabolism , Myocardium/metabolism , Peroxisome Proliferator-Activated Receptors/genetics , Absorptiometry, Photon , Animals , Blotting, Western , Cell Line , Ceramides/metabolism , Diacylglycerol O-Acyltransferase/deficiency , Diacylglycerol O-Acyltransferase/genetics , Diglycerides/metabolism , Echocardiography , Enzyme Inhibitors/pharmacology , Gene Expression/drug effects , Gene Expression/genetics , Glucose/metabolism , Lipoproteins, VLDL/metabolism , Male , Mice , Mice, Knockout , Myoblasts/drug effects , Myoblasts/metabolism , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism , Organ Size/genetics , Palmitic Acid/pharmacology , Polymerase Chain Reaction
5.
J Clin Invest ; 117(10): 2791-801, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17823655

ABSTRACT

Three forms of PPARs are expressed in the heart. In animal models, PPARgamma agonist treatment improves lipotoxic cardiomyopathy; however, PPARgamma agonist treatment of humans is associated with peripheral edema and increased heart failure. To directly assess effects of increased PPARgamma on heart function, we created transgenic mice expressing PPARgamma1 in the heart via the cardiac alpha-myosin heavy chain (alpha-MHC) promoter. PPARgamma1-transgenic mice had increased cardiac expression of fatty acid oxidation genes and increased lipoprotein triglyceride (TG) uptake. Unlike in cardiac PPARalpha-transgenic mice, heart glucose transporter 4 (GLUT4) mRNA expression and glucose uptake were not decreased. PPARgamma1-transgenic mice developed a dilated cardiomyopathy associated with increased lipid and glycogen stores, distorted architecture of the mitochondrial inner matrix, and disrupted cristae. Thus, while PPARgamma agonists appear to have multiple beneficial effects, their direct actions on the myocardium have the potential to lead to deterioration in heart function.


Subject(s)
Cardiomyopathy, Dilated/genetics , Lipid Metabolism , PPAR gamma/metabolism , Aging/genetics , Animals , Cardiomyopathy, Dilated/pathology , Cardiomyopathy, Dilated/physiopathology , Fatty Acids/metabolism , Gene Expression , Gene Expression Regulation , Glucose/metabolism , Glucose Transporter Type 4/genetics , Glucose Transporter Type 4/metabolism , Glycogen/metabolism , Heart/physiopathology , Lipid Metabolism/genetics , Mice , Mice, Transgenic , PPAR gamma/agonists , PPAR gamma/genetics , Promoter Regions, Genetic/genetics , Rosiglitazone , Thiazolidinediones/pharmacology , Ventricular Myosins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...